investors.aridispharma.comAridis Pharmaceuticals - Welcome

Company Company Overview Board of Directors Executive Team Advisory Board Pipeline Product Overview AR-301 (Salvecin ® ) AR-320 (Suvratoxumab) AR-105 (Aerucin ® )AR-501 (Panaecin ™ ) AR-712 (COVID-19 mAb) AR-701 (COVID-19 mAb) Preclinical AR-401 Out-licensed Products AR-105 (Aerucin ® ) AR-101 (Aerumab ™ ) AR-201 TECHNOLOGY Technology Overview APEX TM MabIgX ® Therapeutic Targets HAP / VAP VAP Prevention Cystic Fibrosis COVID-19 Disease Investors Welcome Corporate Governance Board of Directors Board Committees News Releases SEC Filings Stock Information Interactive Chart Investment Calculator Historical Stock Price Analyst Coverage Events and Webcasts Publications and Posters Investor alerts Investor Inquiries Contact Us Contact Us Careers Company Company Overview Board of Directors Executive Team Advisory Board Pipeline Product Overview AR-301 (Tosatoxumab) AR-320 (Suvratoxumab) AR-501 (Panaecin ™ ) AR-712 (COVID-19 mAb) AR-701 (COVID-19 mAb) Preclinical AR-401 Out-licensed Products AR-105 (Aerucin ® ) AR-101 (Aerumab TM ) AR-201 TECHNOLOGY Overview MabIgX ® Therapeutic Targets HAP / VAP VAP Prevention Cystic Fibrosis COVID-19 Disease Investors Welcome Corporate Governance Board of Directors Board Committees News Releases SEC Filings Stock Information Interactive Chart Investment Calculator Historical Stock Price Analyst Coverage Events and Webcasts Publications and Posters Investor alerts Investor Inquiries Contact Us Contact Us Careers Search: Investors Welcome Aridis is a late‑stage biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life‑threatening infections. mAbs represent an innovative treatment approach that harnesses the human immune system to fight infections and are designed to overcome the deficiencies associated with current therapies, such as rise in drug resistance, short duration of response, negative impact on the human microbiome, and lack of differentiation among the treatment alternatives. The majority of Aridis’ product candidates are derived by employing a differentiated antibody discovery platform called MabIgX. The proprietary product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life‑threatening bacterial infections, primarily hospital‑acquired pneumonia, or HAP, and ventilator‑associated pneumonia, or VAP. Three of these product candidates have exhibited promising preclinical data and clinical data are available from two completed studies and are in pivotal trial stage. The Company’s lead product candidate, AR‑301, targets the alpha toxin produced by gram‑positive bacteria Staphylococcus aureus , or S. aureus, a common pathogen associated with HAP and VAP. Aridis conducted an end‑of‑Phase 2 meeting with the U.S. Food and Drug Administration, or FDA, and initiated Phase 3 study in 1H2019. Recent News Investor alerts Oct 4, 2022 Aridis Announces the Closing of Patient Enrollment in the AR-301 Global Phase 3 Superiority Study On track to complete data compilation and analyses, with top-line data expected to be announced in December '22 LOS GATOS, Calif., Oct. 4, 2022 /PRNewswire/Aridis Pharmaceuticals, Inc.... Sep 27, 2022 Aridis Pharmaceuticals Announces Withdrawal of Public Offering of Common Stock Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today... Sep 26, 2022 Aridis Pharmaceuticals Announces Proposed Public Offering of Common Stock Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today... OTCQB ARDS 1dy 1mo 6mo 1yr 5yr Stock Info OTCQB ARDS CONTACT US Aridis Pharmaceuticals Inc. 983 University Ave Suite B Los Gatos, CA 95032 Phone: 408-385-1742 Fax: 408-960-3822 ADDITIONAL INFORMATION Site Map Privacy Policy Financial Conflict of Interest Policy LATEST NEWS Aridis Pharmaceuticals, Inc. Appoints Wolfgang Dummer, M.D., Ph.D., as Chief Medical Officer, and Mitchell H. Rosner, Ph.D. as Vice President of Quality March 5, 2018 Aridis Pharmaceuticals Forms Subsidiary to Develop and Market its Monoclonal Antibody Therapies in China. February 27,...